382:(vascular endothelial growth factor A). The various symptoms and biological profile of long COVID clearly show that there are very different clinical and biological entities. This discovery opened up new avenues for the treatment of long COVID symptoms, particularly those affecting the lungs. It led to the launch of the first therapeutic trial for long COVID, funded by the French PHRC (Programme Hospitalier de Recherche Clinique) for infectious diseases in 2024. David Smadja has also been a strong advocate for the recognition that long COVID is not a single condition but rather a collection of multiple, distinct diseases. His work emphasizes the need for a more nuanced understanding of the varied manifestations of long COVID in order to develop more targeted treatments and management strategies.
264:(ECFCs), their tissue and molecular origins remained unclear. In 2015, Smadja’s work led to the discovery that very small embryonic-like stem cells (VSELs), specifically from CD133-positive cells in humans, could give rise to endothelial cells. Later, in collaboration with the University of Louisville, he demonstrated that CD34+ VSELs could differentiate into the vasculogenic subtype of EPCs, known as ECFCs. Smadja authored the first international consensus paper on the technical methods for isolating and cultivating ECFCs. In 2023, he proposed a second consensus paper based on an international survey of practices in endothelial progenitor cell culture, reinforcing his contributions to the field.
324:, David Smadja recognized the potential impact of the virus on vascular health and began investigating the associated endothelial dysfunction, or endotheliopathy, and the related coagulopathy in COVID-19 patients. His research aimed to understand how the virus triggers widespread vascular damage, leading to abnormal blood clotting, a hallmark of severe COVID-19 cases. Recognizing the urgency of the situation, he submitted a research proposal to study these phenomena and was awarded one of the first grants from the French Ministry of Research in March 2020 for SARCODO Study.
328:
of COVID-19 and highlighted the importance of understanding endothelial health in managing the disease. By exploring both the endothelial dysfunction and the resulting coagulopathy, Smadja contributed to the growing body of research that underscores the systemic nature of COVID-19, beyond its initial respiratory presentation. According to a paper published in
Heliyon, he has been cited worldwide as the number one researcher in this field. His work advanced understanding of how COVID-19 affects blood clotting mechanisms and related vascular disorders.
370:
mass vaccination was both a public health necessity and a moral responsibility to protect vulnerable populations and relieve healthcare systems. This stance attracted significant attention and debate, especially when French
President Emmanuel Macron introduced the vaccine pass, requiring proof of vaccination for access to public venues. Smadja and other experts stressed the importance of vaccination in controlling the virus, especially with more transmissible variants emerging.
394:. The Aeson® heart's includes hemodynamics that closely mimic natural heart function, a hybrid membrane, and bioprosthetic valves made from bovine pericardium, in which are intended to ensure compatibility with the body's circulatory system. Smadja's research demonstrated that the Aeson® heart does not lead to any signs of acquired von Willebrand syndrome, nor other biological or clinical issues indicating poor hemocompatibility, such as
30:
182:(2018-2022), and serving as a member of both the scientific council and the board of directors of INNOVTE (Investigation Network On Venous Thrombo-Embolism). INNOVTE is a national network, accredited by F-CRIN, dedicated to advancing clinical and translational research, as well as European-scale studies on venous thromboembolic disease (VTE).
331:
David Smadja's contributions helped in advancing treatments and management strategies for patients facing complications related to vascular dysfunction, particularly through the use of anticoagulation therapies. Notably, during the first wave of the COVID-19 pandemic in 2020, Smadja, in collaboration
1896:
Smadja, David M.; Ivak, Peter; Pya, Yuri; Latremouille, Christian; Gustafsson, Finn; Roussel, Jean
Christian; Vincentelli, Andre; Flecher, Erwan; Jansen, Piet; Netuka, Ivan (September 2022). "Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic
432:
Smadja, David M.; Bièche, Ivan; Uzan, Georges; Bompais, Heidi; Muller, Laurent; Boisson-Vidal, Catherine; Vidaud, Michel; Aiach, Martine; Gaussem, Pascale (November 2005). "PAR-1 Activation on Human Late
Endothelial Progenitor Cells Enhances Angiogenesis In Vitro With Upregulation of the SDF-1/CXCR4
327:
This early funding allowed him to investigate the mechanisms by which SARS-CoV-2 disrupts the vascular system, focusing on how endothelial injury contributes to the severe clotting complications seen in COVID-19, such as microvascular thrombosis. His work provided insights into the vascular aspects
1172:
Billoir, Paul; Blandinières, Adeline; Gendron, Nicolas; Chocron, Richard; Gunther, Sven; Philippe, Aurélien; Guerin, Coralie L.; Israël-Biet, Dominique; Smadja, David M. (April 2021). "Endothelial Colony-Forming Cells from
Idiopathic Pulmonary Fibrosis Patients Have a High Procoagulant Potential".
557:
Van Huyen, Jean-Paul Duong; Smadja, David M; Bruneval, Patrick; Gaussem, Pascale; Dal-Cortivo, Liliane; Julia, Pierre; Fiessinger, Jean-Noël; Cavazzana-Calvo, Marina; Aiach, Martine; Emmerich, Joseph (July 2008). "Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local
476:
Smadja, David M.; d'Audigier, Clément; Bièche, Ivan; Evrard, Solène; Mauge, Laetitia; Dias, Juliana-Vieira; Labreuche, Julien; Laurendeau, Ingrid; Marsac, Bérengère; Dizier, Blandine; Wagner-Ballon, Orianne; Boisson-Vidal, Catherine; Morandi, Verônica; Duong-Van-Huyen, Jean-Paul; Bruneval, Patrick
369:
David Smadja strongly advocated for widespread COVID-19 vaccination, emphasizing its importance for controlling the pandemic. Alongside a French lawyer, he supported making vaccination legally mandatory, proposing that unvaccinated individuals face restrictions in public spaces. Smadja argued that
625:
Smadja, David M.; Bièche, Ivan; Silvestre, Jean-Sébastien; Germain, Stéphane; Cornet, Adeline; Laurendeau, Ingrid; Duong-Van-Huyen, Jean-Paul; Emmerich, Joseph; Vidaud, Michel; Aiach, Martine; Gaussem, Pascale (December 2008). "Bone
Morphogenetic Proteins 2 and 4 Are Selectively Expressed by Late
1766:
Smadja, David M.; Saubaméa, Bruno; Susen, Sophie; Kindo, Michel; Bruneval, Patrick; Van Belle, Eric; Jansen, Piet; Roussel, Jean-Christian; Latrémouille, Christian; Carpentier, Alain (July 2017). "Bioprosthetic Total
Artificial Heart Induces a Profile of Acquired Hemocompatibility With Membranes
937:
Blandinières, Adeline; Randi, Anna M.; Paschalaki, Koralia E.; Guerin, Coralie L.; Melero-Martin, Juan M.; Smadja, David M. (September 2023). "Results of an international survey about methods used to isolate human endothelial colony-forming cells: guidance from the SSC on
Vascular Biology of the
1696:
Philippe, Aurélien; Günther, Sven; Rancic, Jeanne; Cavagna, Pauline; Renaud, Bertrand; Gendron, Nicolas; Mousseaux, Elie; Hua-Huy, Thông; Reverdito, Guillaume; Planquette, Benjamin; Sanchez, Olivier; Gaussem, Pascale; Salmon, Dominique; Diehl, Jean-Luc; Smadja, David M. (February 2024). "VEGF-A
1216:
Smadja, David M.; Mauge, Laetitia; Nunes, Hilario; d’Audigier, Clément; Juvin, Karine; Borie, Raphael; Carton, Zohra; Bertil, Sébastien; Blanchard, Anne; Crestani, Bruno; Valeyre, Dominique; Gaussem, Pascale; Israel-Biet, Dominique (January 2013). "Imbalance of circulating endothelial cells and
1126:
Bacha, Nour C.; Blandinieres, Adeline; Rossi, Elisa; Gendron, Nicolas; Nevo, Nathalie; Lecourt, SĂ©verine; Guerin, Coralie L.; Renard, Jean Marie; Gaussem, Pascale; Angles-Cano, Eduardo; Boulanger, Chantal M.; Israel-Biet, Dominique; Smadja, David M. (April 2018). "Endothelial
Microparticles are
975:
Smadja, David M.; Gaussem, Pascale; Mauge, Laetitia; Israël-Biet, Dominique; Dignat-George, Françoise; Peyrard, Séverine; Agnoletti, Gabriella; Vouhé, Pascal R.; Bonnet, Damien; Lévy, Marilyne (27 January 2009). "Circulating
Endothelial Cells: A New Candidate Biomarker of Irreversible Pulmonary
781:
Guerin, Coralie L.; Loyer, Xavier; Vilar, José; Cras, Audrey; Mirault, Tristan; Gaussem, Pascale; Silvestre, Jean-Sébastien; Smadja, David M. (September 2015). "Bone-marrow-derived very small embryonic-like stem cells in patients with critical leg ischaemia: evidence of vasculogenic potential".
1850:
Poitier, Bastien; Chocron, Richard; Peronino, Christophe; Philippe, Aurélien; Pya, Yuri; Rivet, Nadia; Richez, Ulysse; Bekbossynova, Mahabbat; Gendron, Nicolas; Grimmé, Marc; Bories, Marie Cécile; Brichet, Julie; Capel, Antoine; Rancic, Jeanne; Vedie, Benoit (April 2022). "Bioprosthetic Total
1082:
Blandinières, Adeline; Gendron, Nicolas; Bacha, Nour; Bièche, Ivan; Chocron, Richard; Nunes, Hilario; Nevo, Nathalie; Rossi, Elisa; Crestani, Bruno; Lecourt, Séverine; Chevret, Sylvie; Lokajczyk, Anna; Mignon, Virginie; Kisaoglu, Alexandre; Juvin, Karine (May 2019). "Interleukin-8 release by
1926:
Dangas, George D.; Tijssen, Jan G.P.; Wöhrle, Jochen; Søndergaard, Lars; Gilard, Martine; Möllmann, Helge; Makkar, Raj R.; Herrmann, Howard C.; Giustino, Gennaro; Baldus, Stephan; De Backer, Ole; Guimarães, Ana H.C.; Gullestad, Lars; Kini, Annapoorna; von Lewinski, Dirk (9 January 2020). "A
1260:
Smadja, David M.; Mentzer, Steven J.; Fontenay, Michaela; Laffan, Mike A.; Ackermann, Maximilian; Helms, Julie; Jonigk, Danny; Chocron, Richard; Pier, Gerald B.; Gendron, Nicolas; Pons, Stephanie; Diehl, Jean-Luc; Margadant, Coert; Guerin, Coralie; Huijbers, Elisabeth J. M. (November 2021).
259:
After two years at Harvard Medical School in Joyce Bischoff's lab in Boston, where he studied how stem cells contribute to vascular formation in infantile hemangioma, David Smadja returned to Paris in 2012 to explore the ontogeny of the endothelial lineage. Despite the growing interest in
595:
Smadja, David M.; Duong-van-Huyen, Jean-Paul; Dal Cortivo, Liliane; Blanchard, Anne; Bruneval, Patrick; Emmerich, Joseph; Gaussem, Pascale (February 2012). "Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemia".
1376:
Philippe, Aurélien; Chocron, Richard; Gendron, Nicolas; Bory, Olivier; Beauvais, Agathe; Peron, Nicolas; Khider, Lina; Guerin, Coralie L.; Goudot, Guillaume; Levasseur, Françoise; Peronino, Christophe; Duchemin, Jerome; Brichet, Julie; Sourdeau, Elise; Desvard, Florence (August 2021).
1469:
Chocron, Richard; Galand, Vincent; Cellier, Joffrey; Gendron, Nicolas; Pommier, Thibaut; Bory, Olivier; Khider, Lina; Trimaille, Antonin; Goudot, Guillaume; Weizman, Orianne; Alsac, Jean Marc; Geneste, Laura; Schmeltz, Armand; Panagides, Vassili; Philippe, Aurélien (20 April 2021).
1318:
Smadja, David M.; Guerin, Coralie L.; Chocron, Richard; Yatim, Nader; Boussier, Jeremy; Gendron, Nicolas; Khider, Lina; Hadjadj, JĂ©rĂ´me; Goudot, Guillaume; Debuc, Benjamin; Juvin, Philippe; Hauw-Berlemont, Caroline; Augy, Jean-Loup; Peron, Nicolas; Messas, Emmanuel (November 2020).
1796:
Richez, Ulysse; De Castilla, Hector; Guerin, Coralie L.; Gendron, Nicolas; Luraghi, Giulia; Grimme, Marc; Wu, Wei; Taverna, Myriam; Jansen, Piet; Latremouille, Christian; Migliavacca, Francesco; Dubini, Gabriele; Capel, Antoine; Carpentier, Alain; Smadja, David M. (December 2019).
1588:
Bérezné, Alice; Bougon, David; Blanc-Jouvan, Florence; Gendron, Nicolas; Janssen, Cecile; Muller, Michel; Bertil, Sébastien; Desvard, Florence; Presot, Isabelle; Terrier, Benjamin; Chocron, Richard; Sanchez, Olivier; Helley, Dominique; Smadja, David M. (August 2021).
336:
might play a protective role in COVID-19. Subsequent large-scale clinical and randomized trials confirmed this hypothesis, showing that early anticoagulation could mitigate the severity of COVID-19 by addressing the coagulation disorders associated with the disease.
414:
processes to extend the lifespan of bioprosthetic materials and improve clinical outcomes. To better understand role of recellularization in biomaterials but also in valve disorders, Smadja is involved in mechanistic studies as evidenced in a FRM publication.
209:—both mature and progenitor cells— and protein biomarkers in the diagnosis, therapy, and regeneration. His work explores the role of endothelial cells in medical applications, including their potential as diagnostic tools, therapeutic targets, or agents in
401:
In a letter published in the New England Journal of Medicine, David Smadja proposed that a crucial factor in preventing thrombosis in bioprosthetic materials is the use of short-term and targeted contact-phase inhibition. He later demonstrated that
365:
was widely confirmed. Smadja’s team published a report on a fatal case of vaccine-induced immune thrombotic thrombocytopenia (VITT) following AstraZeneca vaccination in France, contributing to the understanding of this rare complication.
332:
with the French Society of Cardiology, demonstrated that patients who were already on oral anticoagulation for other medical conditions experienced less severe forms of COVID-19. This early observation led to the hypothesis that
312:
in the absence of infection due to endothelial disorders, particularly an increased senescent and prothrombotic profile of endothelial cells. His work demonstrated that ECFCs are significantly decreased in stable IPF patients.
185:
From 2019 to 2021, Smadja served as the Director of the Bio-Surgical Research Laboratory at the Carpentier Foundation, where he managed the large animal platform facility. Since 2021, he has served as an Associate Editor for
349:'s pharmacovigilance department tasked David Smadja with assessing the risk of thrombosis after vaccination. His evaluation revealed that the rate of reported thrombotic events following the administration of three vaccines—
1639:
233:. During his PhD, David Smadja delved into the study of EPCs, focusing on their characterization and role in vessel formation. He explored how these cells interact with the coagulation system, particularly with
827:
Domingues, Alison; Rossi, Elisa; Bujko, Kamila; Detriche, Grégoire; Richez, Ulysse; Blandinieres, Adeline; Kucia, Magdalena; Ratajczak, Janina; Smadja, David M.; Ratajczak, Mariusz Z. (May 2022).
1668:
268:
308:
and as an indicator of patient response to vasodilator treatments. In IPF, Smadja’s research provided insights into the underlying vascular dysfunction, including the recruitment of
390:
David Smadja has contributed to research on the hemocompatibility of the Carmat Aeson® total artificial heart, a pulsatile artificial heart designed for patients with biventricular
175:
He is currently a university professor at Paris Cité University and a hospital practitioner in the hematology department of the Georges Pompidou European Hospital, part of AP-HP.
361:—was extremely low, confirming the rarity of such adverse effects. While a few cases of thrombosis following the AstraZeneca vaccine exhibited an atypical profile, the safety of
512:
Silvestre, Jean-SĂ©bastien; Smadja, David M.; LĂ©vy, Bernard I. (October 2013). "Postischemic Revascularization: From Cellular and Molecular Mechanisms to Clinical Applications".
1591:"Deterioration of vaccine-induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay"
829:"Human CD34+ very small embryonic-like stem cells can give rise to endothelial colony-forming cells with a multistep differentiation strategy using UM171 and nicotinamide acid"
398:
or thrombosis. Additionally, his work revealed the endothelialization of the ventricular membrane, which likely contributes to the device's low anticoagulation requirements.
179:
1853:
628:
191:
197:
In 2005, he received an award from the French National Society of Hemostasis and Thrombosis for his research on thrombin activation in endothelial progenitor cells.
378:
In 2023, David Smadja's team highlighted a significant link between the pulmonary forms of long COVID and a marker associated with abnormal blood vessel formation:
1899:
1769:
164:. In 2006, he completed his PhD in Basic Sciences at the same university. From 2010 to 2012, he served as a research fellow in the Vascular Biology Program at
477:(March 2011). "Thrombospondin-1 Is a Plasmatic Marker of Peripheral Arterial Disease That Modulates Endothelial Progenitor Cell Angiogenic Properties".
1476:
358:
271:, David Smadja’s team received the "FRANCE 2030 PEPR Biotherapies" grant for the "Bioengineered Skin France" project. The project aims to enhance
121:
93:
1379:"Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality"
292:
In the late 2000s, David Smadja and his team proposed that the pulmonary endothelium is an active organ in pulmonary diseases, particularly in
1021:
Levy, Marilyne; Bonnet, Damien; Mauge, Laetitia; Celermajer, David S.; Gaussem, Pascale; Smadja, David M. (10 June 2013). West, James (ed.).
940:
892:
350:
1978:
379:
1740:
1929:
1321:"Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients"
1472:"Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study"
1023:"Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening"
125:
677:
1083:
endothelial colony-forming cells isolated from idiopathic pulmonary fibrosis patients might contribute to their pathogenicity".
886:
Smadja, David M.; Melero-Martin, Juan M.; Eikenboom, Jeroen; Bowman, Mackenzie; Sabatier, Florence; Randi, Anna M. (July 2019).
261:
1640:"«La loi doit sanctionner ceux qui refusent le vaccin et transmettent le virus» : l'appel d'un médecin et d'un avocat"
2049:
1129:
297:
187:
169:
1851:
Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor".
1535:
301:
722:
Smadja, David M.; Guerin, Coralie L.; Boscolo, Elisa; Bieche, Ivan; Mulliken, John B.; Bischoff, Joyce (1 March 2014).
279:
content and incorporating prerevascularization strategies with ECFCs, while also focusing on reducing graft rejection.
222:
205:
David Smadja's research primarily focuses on the circulating endothelial compartment, with an emphasis on the role of
97:
190:
and is a member of the editorial board for the Angiogenesis journal. He previously served on the editorial board of
1972:
Poitier, Bastien; Rancic, Jeanne; Richez, Ulysse; Piquet, Julie; El Batti, Salma; Smadja, David M. (31 July 2023).
888:"Standardization of methods to quantify and culture endothelial colony-forming cells derived from peripheral blood"
784:
560:
161:
410:
in bioprosthetic devices, potentially reducing their longevity. His insights highlight the importance of managing
673:"E-Selectin Mediates Stem Cell Adhesion and Formation of Blood Vessels in a Murine Model of Infantile Hemangioma"
346:
1531:"Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase"
354:
129:
77:
Hematology, Hemostasis, Thrombosis, Endothelial progenitor cells, COVID-19, Long covid, Cardiovascular disease
140:
and vascular biology. Smadja has contributed to research on vascular and coagulation disorders associated to
1974:"Fibrin deposition on bovine pericardium tissue used for bioprosthetic heart valve drives its calcification"
305:
2039:
293:
165:
1529:
Smadja, David M.; Yue, Qun-Ying; Chocron, Richard; Sanchez, Olivier; Lillo-Le Louet, Agnes (July 2021).
978:
598:
514:
210:
345:
In March 2021, when the first cases of thrombosis were suspected following COVID-19 vaccinations, the
2044:
728:
249:
1697:
plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients".
300:(IPF), marked by the destruction of alveolar architecture. In the context of PH, Smadja introduced
833:
225:(EPCs) in 1997 was a key advancement in vascular biology, opening new possibilities for treating
2054:
2015:
1997:
1954:
1946:
1878:
1870:
1832:
1722:
1714:
1669:"Covid long : «Une cible thérapeutique intéressante» identifiée par une équipe française"
1620:
1570:
1552:
1511:
1493:
1416:
1398:
1358:
1340:
1300:
1282:
1242:
1234:
1198:
1190:
1154:
1146:
1108:
1100:
1064:
1046:
1003:
995:
957:
919:
868:
850:
809:
801:
763:
745:
724:"α6-Integrin Is Required for the Adhesion and Vasculogenic Potential of Hemangioma Stem Cells"
704:
653:
645:
577:
539:
531:
494:
458:
450:
321:
2005:
1987:
1938:
1908:
1862:
1822:
1812:
1778:
1706:
1610:
1602:
1560:
1544:
1501:
1485:
1449:
1406:
1390:
1348:
1332:
1290:
1274:
1226:
1182:
1138:
1092:
1054:
1036:
987:
949:
909:
901:
858:
842:
793:
753:
737:
694:
686:
637:
607:
569:
523:
486:
442:
226:
113:
157:
1263:"COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects"
2010:
1973:
1827:
1798:
1615:
1590:
1565:
1530:
1506:
1471:
1411:
1378:
1353:
1320:
1295:
1262:
1059:
1022:
914:
887:
863:
828:
758:
723:
699:
672:
446:
238:
991:
2033:
1673:
407:
391:
333:
272:
275:
technology by boosting the regenerative capacity of grafts, primarily by increasing
178:
His professional roles also include co-chairing the vascular biology session of the
362:
248:
Smadja also played a role in the OPTIPEC trial, a cell therapy trials for critical
230:
1817:
1799:"Hemocompatibility and safety of the Carmat Total Artifical Heart hybrid membrane"
1454:
1435:
1912:
1041:
690:
611:
1644:
1548:
411:
253:
206:
1927:
Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement".
1866:
1782:
1710:
1394:
1336:
1278:
1186:
1096:
953:
846:
641:
527:
490:
256:
into distal tissues of the lower limb could stimulate a neoangiogenic process.
1992:
1230:
1142:
573:
317:
309:
267:
In 2023, under the leadership of Nicolas Fortunel, a research director at the
145:
137:
133:
117:
2001:
1950:
1874:
1718:
1556:
1497:
1402:
1344:
1286:
1238:
1194:
1150:
1104:
1050:
999:
854:
805:
749:
649:
535:
498:
454:
1489:
395:
276:
2019:
1958:
1882:
1836:
1726:
1624:
1574:
1515:
1420:
1362:
1304:
1246:
1202:
1158:
1112:
1068:
1007:
961:
923:
872:
813:
767:
708:
657:
581:
543:
462:
1942:
29:
1027:
797:
242:
234:
141:
1803:
1606:
1440:
1741:"Covid long: un pas vers un test sanguin pour faciliter le diagnostic"
905:
741:
671:
Smadja, David M.; Mulliken, John B.; Bischoff, Joyce (December 2012).
304:(CECs) as a clinical biomarker to evaluate the reversibility of PH in
626:
Outgrowth Endothelial Progenitor Cells and Promote Neoangiogenesis".
403:
85:
89:
1436:"COVID-19 associated coagulopathy: A bibliometric investigation"
1127:
Associated to Pathogenesis of Idiopathic Pulmonary Fibrosis".
241:. His research provided insights into how EPCs contribute to
156:
In 2005, he obtained his Diploma of Specialized Studies in
217:
Endothelial progenitor cells and vascular regeneration
976:
Hypertension Secondary to Congenital Heart Disease".
1638:Fellous, Benjamin; Smadja, David (9 January 2022).
1595:
Research and Practice in Thrombosis and Haemostasis
180:
International Society on Thrombosis and Haemostasis
81:
73:
58:
36:
20:
1854:Arteriosclerosis, Thrombosis, and Vascular Biology
629:Arteriosclerosis, Thrombosis, and Vascular Biology
479:Arteriosclerosis, Thrombosis, and Vascular Biology
435:Arteriosclerosis, Thrombosis, and Vascular Biology
192:Arteriosclerosis, Thrombosis, and Vascular Biology
386:Heart valve and hemocompatibility of biomaterials
288:Role of endothelial cells in human lung diseases
1217:progenitors in idiopathic pulmonary fibrosis".
1900:The Journal of Heart and Lung Transplantation
1770:Journal of the American College of Cardiology
406:formation, and likely thrombosis, accelerate
8:
245:, vascular repair and vessel regeneration.
17:
2009:
1991:
1826:
1816:
1614:
1564:
1505:
1477:Journal of the American Heart Association
1453:
1410:
1352:
1294:
1058:
1040:
913:
862:
757:
698:
283:COVID-19 as an acquired vascular disorder
252:. This study demonstrated that injecting
424:
374:Long Covid could be a vascular disorder
168:, within the Department of Surgery at
120:working as a hospital practitioner in
92:(Greater Paris University Hospitals),
941:Journal of Thrombosis and Haemostasis
893:Journal of Thrombosis and Haemostasis
558:injection in critical leg ischemia".
316:In early 2020, with the emergence of
7:
1979:Frontiers in Cardiovascular Medicine
1930:The New England Journal of Medicine
447:10.1161/01.ATV.0000184762.63888.bd
122:Georges Pompidou European Hospital
14:
992:10.1161/CIRCULATIONAHA.108.808246
678:The American Journal of Pathology
269:Commissariat à l'Énergie Atomique
94:Hôpital Européen Georges-Pompidou
1897:artificial heart implantation".
262:endothelial colony-forming cells
28:
1434:Alshakh, Nahla A. (June 2023).
160:specialized in hematology from
1:
1818:10.1016/j.heliyon.2019.e02914
1455:10.1016/j.heliyon.2023.e16507
1175:Stem Cell Reviews and Reports
1130:Stem Cell Reviews and Reports
302:circulating endothelial cells
298:idiopathic pulmonary fibrosis
188:Stem Cell Reviews and Reports
1913:10.1016/j.healun.2022.05.017
1747:(in French). 19 January 2024
1536:European Respiratory Journal
1042:10.1371/journal.pone.0065114
691:10.1016/j.ajpath.2012.08.030
612:10.3109/14653249.2011.627917
223:endothelial progenitor cells
148:during the global pandemic.
112:(born February 25, 1978, in
1549:10.1183/13993003.00956-2021
2071:
1867:10.1161/ATVBAHA.121.316833
1783:10.1016/j.jacc.2017.05.021
1711:10.1007/s10456-023-09890-9
1395:10.1007/s10456-020-09762-6
1337:10.1007/s10456-020-09730-0
1279:10.1007/s10456-021-09805-6
1187:10.1007/s12015-020-10043-4
1097:10.1007/s10456-018-09659-5
954:10.1016/j.jtha.2023.06.014
847:10.1038/s41375-022-01517-0
785:Thrombosis and Haemostasis
642:10.1161/ATVBAHA.108.168815
528:10.1152/physrev.00006.2013
491:10.1161/ATVBAHA.110.220624
170:Boston Children's Hospital
162:Paris Descartes University
1993:10.3389/fcvm.2023.1198020
1231:10.1007/s10456-012-9306-9
1143:10.1007/s12015-017-9778-5
574:10.1038/modpathol.2008.48
347:World Health Organization
103:
66:
27:
306:congenital heart disease
53:Clermont-Ferrand, France
1490:10.1161/JAHA.120.018624
221:The discovery of adult
294:pulmonary hypertension
172:in the United States.
166:Harvard Medical School
116:, France) is a French
1943:10.1056/NEJMoa1911425
515:Physiological Reviews
320:and the onset of the
211:regenerative medicine
130:Paris Cité University
98:Université Paris Cité
2050:French hematologists
1767:Recellularization".
798:10.1160/TH14-09-0748
341:Covid-19 vaccination
152:Education and Career
132:. He specializes in
1607:10.1002/rth2.12572
906:10.1111/jth.14462
742:10.1002/stem.1539
636:(12): 2137–2143.
441:(11): 2321–2327.
322:COVID-19 pandemic
227:vascular diseases
207:endothelial cells
107:
106:
68:Scientific career
47:February 25, 1978
2062:
2024:
2023:
2013:
1995:
1969:
1963:
1962:
1923:
1917:
1916:
1907:(9): 1214–1217.
1893:
1887:
1886:
1847:
1841:
1840:
1830:
1820:
1793:
1787:
1786:
1763:
1757:
1756:
1754:
1752:
1737:
1731:
1730:
1693:
1687:
1686:
1684:
1682:
1667:Monod, Olivier.
1664:
1658:
1657:
1655:
1653:
1635:
1629:
1628:
1618:
1585:
1579:
1578:
1568:
1526:
1520:
1519:
1509:
1466:
1460:
1459:
1457:
1431:
1425:
1424:
1414:
1373:
1367:
1366:
1356:
1315:
1309:
1308:
1298:
1257:
1251:
1250:
1213:
1207:
1206:
1169:
1163:
1162:
1123:
1117:
1116:
1079:
1073:
1072:
1062:
1044:
1018:
1012:
1011:
972:
966:
965:
948:(9): 2611–2619.
934:
928:
927:
917:
900:(7): 1190–1194.
883:
877:
876:
866:
841:(5): 1440–1443.
824:
818:
817:
792:(5): 1084–1094.
778:
772:
771:
761:
719:
713:
712:
702:
685:(6): 2239–2247.
668:
662:
661:
622:
616:
615:
592:
586:
585:
561:Modern Pathology
554:
548:
547:
522:(4): 1743–1802.
509:
503:
502:
473:
467:
466:
429:
114:Clermont Ferrand
50:
46:
44:
32:
18:
2070:
2069:
2065:
2064:
2063:
2061:
2060:
2059:
2030:
2029:
2028:
2027:
1971:
1970:
1966:
1925:
1924:
1920:
1895:
1894:
1890:
1849:
1848:
1844:
1795:
1794:
1790:
1765:
1764:
1760:
1750:
1748:
1745:Le Figaro Santé
1739:
1738:
1734:
1695:
1694:
1690:
1680:
1678:
1666:
1665:
1661:
1651:
1649:
1637:
1636:
1632:
1587:
1586:
1582:
1528:
1527:
1523:
1468:
1467:
1463:
1433:
1432:
1428:
1375:
1374:
1370:
1317:
1316:
1312:
1259:
1258:
1254:
1215:
1214:
1210:
1171:
1170:
1166:
1125:
1124:
1120:
1081:
1080:
1076:
1020:
1019:
1015:
974:
973:
969:
936:
935:
931:
885:
884:
880:
826:
825:
821:
780:
779:
775:
721:
720:
716:
670:
669:
665:
624:
623:
619:
594:
593:
589:
556:
555:
551:
511:
510:
506:
475:
474:
470:
431:
430:
426:
421:
388:
376:
351:Pfizer-BioNTech
343:
334:anticoagulation
290:
285:
219:
203:
158:Medical biology
154:
110:David M. Smadja
54:
51:
48:
42:
40:
23:
12:
11:
5:
2068:
2066:
2058:
2057:
2052:
2047:
2042:
2032:
2031:
2026:
2025:
1964:
1937:(2): 120–129.
1918:
1888:
1861:(4): 470–480.
1842:
1811:(12): e02914.
1788:
1777:(3): 404–406.
1758:
1732:
1688:
1659:
1630:
1580:
1543:(1): 2100956.
1521:
1484:(8): e018624.
1461:
1426:
1389:(3): 505–517.
1368:
1331:(4): 611–620.
1310:
1273:(4): 755–788.
1252:
1225:(1): 147–157.
1208:
1181:(2): 694–699.
1164:
1137:(2): 223–235.
1118:
1091:(2): 325–339.
1074:
1013:
986:(3): 374–381.
967:
929:
878:
819:
773:
736:(3): 684–693.
714:
663:
617:
606:(2): 232–239.
587:
568:(7): 837–846.
549:
504:
485:(3): 551–559.
468:
423:
422:
420:
417:
387:
384:
375:
372:
342:
339:
289:
286:
284:
281:
239:thrombospondin
218:
215:
202:
199:
153:
150:
124:, part of the
105:
104:
101:
100:
83:
79:
78:
75:
71:
70:
64:
63:
60:
56:
55:
52:
38:
34:
33:
25:
24:
21:
13:
10:
9:
6:
4:
3:
2:
2067:
2056:
2053:
2051:
2048:
2046:
2043:
2041:
2040:Living people
2038:
2037:
2035:
2021:
2017:
2012:
2007:
2003:
1999:
1994:
1989:
1985:
1981:
1980:
1975:
1968:
1965:
1960:
1956:
1952:
1948:
1944:
1940:
1936:
1932:
1931:
1922:
1919:
1914:
1910:
1906:
1902:
1901:
1892:
1889:
1884:
1880:
1876:
1872:
1868:
1864:
1860:
1856:
1855:
1846:
1843:
1838:
1834:
1829:
1824:
1819:
1814:
1810:
1806:
1805:
1800:
1792:
1789:
1784:
1780:
1776:
1772:
1771:
1762:
1759:
1746:
1742:
1736:
1733:
1728:
1724:
1720:
1716:
1712:
1708:
1704:
1700:
1692:
1689:
1676:
1675:
1670:
1663:
1660:
1647:
1646:
1641:
1634:
1631:
1626:
1622:
1617:
1612:
1608:
1604:
1601:(6): e12572.
1600:
1596:
1592:
1584:
1581:
1576:
1572:
1567:
1562:
1558:
1554:
1550:
1546:
1542:
1538:
1537:
1532:
1525:
1522:
1517:
1513:
1508:
1503:
1499:
1495:
1491:
1487:
1483:
1479:
1478:
1473:
1465:
1462:
1456:
1451:
1448:(6): e16507.
1447:
1443:
1442:
1437:
1430:
1427:
1422:
1418:
1413:
1408:
1404:
1400:
1396:
1392:
1388:
1384:
1380:
1372:
1369:
1364:
1360:
1355:
1350:
1346:
1342:
1338:
1334:
1330:
1326:
1322:
1314:
1311:
1306:
1302:
1297:
1292:
1288:
1284:
1280:
1276:
1272:
1268:
1264:
1256:
1253:
1248:
1244:
1240:
1236:
1232:
1228:
1224:
1220:
1212:
1209:
1204:
1200:
1196:
1192:
1188:
1184:
1180:
1176:
1168:
1165:
1160:
1156:
1152:
1148:
1144:
1140:
1136:
1132:
1131:
1122:
1119:
1114:
1110:
1106:
1102:
1098:
1094:
1090:
1086:
1078:
1075:
1070:
1066:
1061:
1056:
1052:
1048:
1043:
1038:
1035:(6): e65114.
1034:
1030:
1029:
1024:
1017:
1014:
1009:
1005:
1001:
997:
993:
989:
985:
981:
980:
971:
968:
963:
959:
955:
951:
947:
943:
942:
933:
930:
925:
921:
916:
911:
907:
903:
899:
895:
894:
889:
882:
879:
874:
870:
865:
860:
856:
852:
848:
844:
840:
836:
835:
830:
823:
820:
815:
811:
807:
803:
799:
795:
791:
787:
786:
777:
774:
769:
765:
760:
755:
751:
747:
743:
739:
735:
731:
730:
725:
718:
715:
710:
706:
701:
696:
692:
688:
684:
680:
679:
674:
667:
664:
659:
655:
651:
647:
643:
639:
635:
631:
630:
621:
618:
613:
609:
605:
601:
600:
591:
588:
583:
579:
575:
571:
567:
563:
562:
553:
550:
545:
541:
537:
533:
529:
525:
521:
517:
516:
508:
505:
500:
496:
492:
488:
484:
480:
472:
469:
464:
460:
456:
452:
448:
444:
440:
436:
428:
425:
418:
416:
413:
409:
408:calcification
405:
399:
397:
393:
392:heart failure
385:
383:
381:
373:
371:
367:
364:
363:mRNA vaccines
360:
356:
352:
348:
340:
338:
335:
329:
325:
323:
319:
314:
311:
307:
303:
299:
295:
287:
282:
280:
278:
274:
270:
265:
263:
257:
255:
251:
250:limb ischemia
246:
244:
240:
236:
232:
228:
224:
216:
214:
212:
208:
200:
198:
195:
193:
189:
183:
181:
176:
173:
171:
167:
163:
159:
151:
149:
147:
143:
139:
135:
131:
127:
123:
119:
115:
111:
102:
99:
95:
91:
87:
84:
80:
76:
72:
69:
65:
61:
57:
49:(age 46)
39:
35:
31:
26:
19:
16:
1983:
1977:
1967:
1934:
1928:
1921:
1904:
1898:
1891:
1858:
1852:
1845:
1808:
1802:
1791:
1774:
1768:
1761:
1751:23 September
1749:. Retrieved
1744:
1735:
1705:(1): 51–66.
1702:
1699:Angiogenesis
1698:
1691:
1681:19 September
1679:. Retrieved
1672:
1662:
1652:17 September
1650:. Retrieved
1643:
1633:
1598:
1594:
1583:
1540:
1534:
1524:
1481:
1475:
1464:
1445:
1439:
1429:
1386:
1383:Angiogenesis
1382:
1371:
1328:
1325:Angiogenesis
1324:
1313:
1270:
1267:Angiogenesis
1266:
1255:
1222:
1219:Angiogenesis
1218:
1211:
1178:
1174:
1167:
1134:
1128:
1121:
1088:
1085:Angiogenesis
1084:
1077:
1032:
1026:
1016:
983:
977:
970:
945:
939:
932:
897:
891:
881:
838:
832:
822:
789:
783:
776:
733:
727:
717:
682:
676:
666:
633:
627:
620:
603:
597:
590:
565:
559:
552:
519:
513:
507:
482:
478:
471:
438:
434:
427:
400:
389:
377:
368:
344:
330:
326:
315:
291:
266:
258:
247:
231:cell therapy
220:
204:
196:
184:
177:
174:
155:
118:hematologist
109:
108:
82:Institutions
67:
22:David Smadja
15:
2045:1978 births
1677:(in French)
1648:(in French)
1645:Le Parisien
979:Circulation
599:Cytotherapy
412:coagulation
359:AstraZeneca
310:neutrophils
254:bone marrow
59:Nationality
2034:Categories
1674:Libération
729:Stem Cells
419:References
318:SARS-CoV-2
273:skin graft
146:long COVID
138:thrombosis
134:hemostasis
43:1978-02-25
2002:2297-055X
1951:0028-4793
1875:1079-5642
1719:0969-6970
1557:0903-1936
1498:2047-9980
1403:0969-6970
1345:0969-6970
1287:0969-6970
1239:0969-6970
1195:2629-3269
1151:1550-8943
1105:0969-6970
1051:1932-6203
1000:0009-7322
855:0887-6924
806:0340-6245
750:1066-5099
650:1079-5642
536:0031-9333
499:1079-5642
455:1079-5642
433:System".
396:hemolysis
296:(PH) and
277:stem cell
2055:COVID-19
2020:37583583
2011:10424437
1959:31733180
1883:35139659
1837:31867454
1727:37526809
1625:34485807
1575:33863748
1516:33550816
1421:33449299
1363:32458111
1305:34184164
1247:22983452
1203:32970229
1159:29101610
1113:30607696
1069:23762293
1028:PLoS ONE
1008:19139384
962:37336438
924:31119878
873:35169243
834:Leukemia
814:25608764
768:24022922
709:23041613
658:18818419
582:18487998
544:24137021
463:16141404
243:ischemia
235:thrombin
229:through
201:Research
142:COVID-19
1828:6906674
1804:Heliyon
1616:8410951
1566:8051185
1507:8174166
1441:Heliyon
1412:7809553
1354:7250589
1296:8238037
1060:3677895
938:ISTH".
915:7028216
864:9061289
759:3944134
700:3509767
355:Moderna
2018:
2008:
2000:
1957:
1949:
1881:
1873:
1835:
1825:
1725:
1717:
1623:
1613:
1573:
1563:
1555:
1514:
1504:
1496:
1419:
1409:
1401:
1361:
1351:
1343:
1303:
1293:
1285:
1245:
1237:
1201:
1193:
1157:
1149:
1111:
1103:
1067:
1057:
1049:
1006:
998:
960:
922:
912:
871:
861:
853:
812:
804:
766:
756:
748:
707:
697:
656:
648:
580:
542:
534:
497:
461:
453:
404:fibrin
380:VEGF-A
357:, and
128:, and
86:Inserm
74:Fields
62:French
126:AP-HP
90:AP-HP
2016:PMID
1998:ISSN
1955:PMID
1947:ISSN
1879:PMID
1871:ISSN
1833:PMID
1753:2024
1723:PMID
1715:ISSN
1683:2024
1654:2024
1621:PMID
1571:PMID
1553:ISSN
1512:PMID
1494:ISSN
1417:PMID
1399:ISSN
1359:PMID
1341:ISSN
1301:PMID
1283:ISSN
1243:PMID
1235:ISSN
1199:PMID
1191:ISSN
1155:PMID
1147:ISSN
1109:PMID
1101:ISSN
1065:PMID
1047:ISSN
1004:PMID
996:ISSN
958:PMID
920:PMID
869:PMID
851:ISSN
810:PMID
802:ISSN
764:PMID
746:ISSN
705:PMID
654:PMID
646:ISSN
578:PMID
540:PMID
532:ISSN
495:ISSN
459:PMID
451:ISSN
237:and
144:and
37:Born
2006:PMC
1988:doi
1939:doi
1935:382
1909:doi
1863:doi
1823:PMC
1813:doi
1779:doi
1707:doi
1611:PMC
1603:doi
1561:PMC
1545:doi
1502:PMC
1486:doi
1450:doi
1407:PMC
1391:doi
1349:PMC
1333:doi
1291:PMC
1275:doi
1227:doi
1183:doi
1139:doi
1093:doi
1055:PMC
1037:doi
988:doi
984:119
950:doi
910:PMC
902:doi
859:PMC
843:doi
794:doi
790:113
754:PMC
738:doi
695:PMC
687:doi
683:181
638:doi
608:doi
570:doi
524:doi
487:doi
443:doi
2036::
2014:.
2004:.
1996:.
1986:.
1984:10
1982:.
1976:.
1953:.
1945:.
1933:.
1905:41
1903:.
1877:.
1869:.
1859:42
1857:.
1831:.
1821:.
1807:.
1801:.
1775:70
1773:.
1743:.
1721:.
1713:.
1703:27
1701:.
1671:.
1642:.
1619:.
1609:.
1597:.
1593:.
1569:.
1559:.
1551:.
1541:58
1539:.
1533:.
1510:.
1500:.
1492:.
1482:10
1480:.
1474:.
1444:.
1438:.
1415:.
1405:.
1397:.
1387:24
1385:.
1381:.
1357:.
1347:.
1339:.
1329:23
1327:.
1323:.
1299:.
1289:.
1281:.
1271:24
1269:.
1265:.
1241:.
1233:.
1223:16
1221:.
1197:.
1189:.
1179:17
1177:.
1153:.
1145:.
1135:14
1133:.
1107:.
1099:.
1089:22
1087:.
1063:.
1053:.
1045:.
1031:.
1025:.
1002:.
994:.
982:.
956:.
946:21
944:.
918:.
908:.
898:17
896:.
890:.
867:.
857:.
849:.
839:36
837:.
831:.
808:.
800:.
788:.
762:.
752:.
744:.
734:32
732:.
726:.
703:.
693:.
681:.
675:.
652:.
644:.
634:28
632:.
604:14
602:.
576:.
566:21
564:.
538:.
530:.
520:93
518:.
493:.
483:31
481:.
457:.
449:.
439:25
437:.
353:,
213:.
194:.
136:,
96:,
88:,
45:)
2022:.
1990::
1961:.
1941::
1915:.
1911::
1885:.
1865::
1839:.
1815::
1809:5
1785:.
1781::
1755:.
1729:.
1709::
1685:.
1656:.
1627:.
1605::
1599:5
1577:.
1547::
1518:.
1488::
1458:.
1452::
1446:9
1423:.
1393::
1365:.
1335::
1307:.
1277::
1249:.
1229::
1205:.
1185::
1161:.
1141::
1115:.
1095::
1071:.
1039::
1033:8
1010:.
990::
964:.
952::
926:.
904::
875:.
845::
816:.
796::
770:.
740::
711:.
689::
660:.
640::
614:.
610::
584:.
572::
546:.
526::
501:.
489::
465:.
445::
41:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
